

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email <a href="mailto:info.bmjopen@bmj.com">info.bmjopen@bmj.com</a>

## **BMJ Open**

Increased use of mental health services among young adults in the aftermath of Covid-19 waves. Results from a retrospective study conducted in a French Psychiatric & Neurosciences University Hospital.

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-064305
Article Type:	Original research
Date Submitted by the Author:	03-May-2022
Complete List of Authors:	PEROZZIELLO, Anne; Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences, Cellule épidémiologie SOUSA, Daniel; Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences, Département d'Information Médicale AUBRIOT, Béatrice; Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences DAURIAC-LE MASSON, Valérie; Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences
Keywords:	MENTAL HEALTH, PSYCHIATRY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, COVID-19

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

- 1 Increased use of mental health services among young adults in the aftermath of
- 2 Covid-19 waves. Results from a retrospective study conducted in a French Psychiatric
- **& Neurosciences University Hospital.**
- 4 Anne Perozziello<sup>1</sup>, Daniel Sousa<sup>2</sup>, Béatrice Aubriot<sup>3</sup>, Valerie Dauriac-Le Masson<sup>2</sup>
- 5 <sup>1</sup> Cellule épidémiologie, GHU Paris Psychiatrie & Neurosciences
- 6 <sup>2</sup> Département d'Information Médicale, GHU Paris Psychiatrie & Neurosciences
- 7 <sup>3</sup> Commission Médicale d'Etablissement, GHU Paris Psychiatrie & Neurosciences
- 8 Corresponding author: Anne PEROZZIELLO GHU Paris Psychiatrie et Neurosciences 1
- 9 rue Cabanis, 75014 PARIS a.perozziello@ghu-paris.fr
- 10 Word count: 2842
- 11 Keywords: mental health; COVID-19; psychiatry; health services use; young adults
- 12 Abstract (276 words)
- Objective: The Covid-19 pandemic and the restrictive measures taken to prevent its
- propagation had profound effects on mental health and well-being, especially in children and
- 15 young adults (< 25 years old). This study aimed to analyse the medium and long-term impact
- of the Covid-19 pandemic on the use of the mental health services, by age groups.
- **Setting**: This study was conducted in the Groupe Hospitalier Universitaire (GHU) Paris
- 18 Psychiatry and Neurosciences. We used the medical and administrative information system
- databases of patients, between 2019 and 2021.
- **Outcome measures**: We reported three indicators: the number of new patient attending
- outpatient clinics, the number of emergency department visits, and the number of hospital
- 22 admissions (full-time).
- **Methods**: We considered the weekly number of each indicator, for all patients and by age
- groups. The 2020 and 2021 data were compared to the same period in 2019. The evolution

of the indicators over the 3 years was analysed with interrupted time-series analysis based on negative binomial regression.

- Results: All three indicators showed a dramatic decrease during the first lockdown period (March 2020) especially for the youngest. In 2021, the activity resumed but without reaching its pre-pandemic level. However, the decrease was not significant between the pre-pandemic and since the beginning of the pandemic for young adults (15-25 years old). They also had a higher level of mental health services use in 2021, compared to 2019: +12% of new patients at the outpatient clinics, +17% of emergency department visits, and +2% of hospital admissions.
- **Conclusions**: The Covid-19 pandemic has had severe consequences on populations' mental health, especially among young people, which seem to persist months after the end of restrictive measures.

#### Strengths and limitation of this study

- Our study was based on systematically collected medical care data provided by the GHU Psychiatry and Neurosciences facilities, over a 3-year period, covering a time before, during and after the Covid-19 pandemic. This large dataset allowed us to describe robust tendencies regarding the use of mental healthcare.
- The GHU Psychiatry and Neurosciences facilities covers a large area (13 of the 20
  Parisian arrondissements are linked to the GHU), so our study represents the use of
  care by a large sample of the population.
- The main limitation is the absence of information on care outside the hospital, such
  as private practitioners, including psychiatrists, psychologists, and general
  practitioners, or other support services, such as helplines.
- From our data, we were not able to distinguish remote medical consultations
   (telemedicine) from face-to-face outpatient appointments and so could not analyse
   the proportion of remote consultations in the activity. We need to understand these

51 changes in providing mental health care and evaluate the therapeutic value and 52 patient satisfaction regarding remote medical appointments.



#### Context

The Covid-19 pandemic and the restrictive measures taken to prevent its propagation (lockdown, curfews, quarantines, movement restrictions etc.) were associated with increased prevalence of major depressive symptoms and anxiety disorders[1–3]. Fear of infection, social media and news exposure, and the consequences of the lockdown (boredom, social isolation, stress, sleeping disorders, pandemic-related uncertainty, loneliness etc.) have had detrimental effects on the mental health and well-being among the population. These effects were more pronounced in some groups, especially children and young adults (< 25 years old)[4–8]. Several studies reported a higher prevalence of mental health problems in young people than older adults[1,9–13]. School and university closures, lack of social interactions and activities, and for students, being confined in small or uncomfortable spaces, away from their families, have worsened the negative effect of Covid-19 on mental health[1,8,14]. In the meantime, the pandemic and the unprecedented measures decided in many countries have led to a drastic decrease in contacts with mental healthcare systems[15–20]. In France, two studies showed a sharp reduction in emergency service visits. The first study, conducted in three psychiatric emergency services in Paris and its suburbs, estimated that during the first weeks of the first lockdown in France (March 17 to May 11, 2020), the number of visits decreased by 54.8% as compared with the same period in 2019[21]. This decrease was statistically significant for the 16-24 years old (-64.4%). The study by Pham et al. analysed the activity of one of the largest Parisian psychiatric emergency services, reporting a significant reduction in visits during the first lockdown as compared with the same period in 2019 (10.8 consultations a day vs 26.4 in 2019)[22]. The authors suggested that patients might have avoided hospitals because of fear of being infected or being sanctioned for not complying with movement restrictions. Moreover, the entire healthcare system was disrupted during the first months of the pandemic, with reduced access to medical facilities and prioritised admissions for severe cases[23].

Therefore, patients faced difficulties accessing appropriate care during this period, which raised fears of a possible psychiatric outbreak post-lockdown and a strong increase in care needs[14,24]. However, despite the lifting of containment measures, the use of healthcare services has returned to pre-pandemic levels, with no substantial increase[25]. Several studies demonstrated an improvement in mental health among the general population after the lifting of the lockdown and a decrease in anxiety and depressive disorders[10,26]. Yet, these findings do not apply evenly across age groups. After intensely experiencing the adverse effects of the lockdown, young people showed persistent depressive and anxiety symptoms and suicidal ideation etc., months after the easing of most restrictions related to Covid-19[26–30].

At the Groupe Hospitalier Universitaire (GHU) Psychiatry and Neurosciences in Paris, a drastic reduction in mental health services use was reported during the first lockdown period, in spring 2020. However, few studies analysed the medium and long-term impact of the Covid-19 pandemic on mental health care use. This study analysed the use of the GHU mental healthcare services between 2019 and 2021, comparing the period before and the period after the "first wave" of Covid-19 (March 2020) for all patients and by age groups.

#### Material and methods

We conducted a retrospective study of data collected from the GHU medical and administrative information system, which includes inpatients' discharge summaries and outpatients' visits for all patients presenting at one of the GHU medical facilities. The GHU Psychiatry and Neurosciences in Paris is the main provider of mental healthcare in the Paris area, with 170 medical services. The GHU represents a catchment area of 1.6 million Parisians.

Patient data are systematically collected in electronic medical records. The physician in charge of the information system extracted weekly data from January 1, 2019 to December 31, 2021 for all patients without exclusion, and summarised by age groups. We analysed

data on the number of new patients at the outpatient clinic, number of visits to the emergency department, and number of hospital admissions (full-time).

The first wave of the Covid-19 pandemic in France started in March 2020. During the first lockdown, from March 17 to May 11, 2020, the government imposed a mandatory home lockdown, with strict restrictions on movement outside the household. Schools and universities as well as non-essential public places, including restaurants, cafés, and cinemas, were closed. On May 11, the lockdown ended, but some measures remained to control the spread of the virus. Social distancing, compulsory mask-wearing (indoor and outdoor), limitations on gatherings, overnight curfew, and teleworking was supported when possible. Primary and middle schools reopened, but high schools and universities remained closed until September 2020, when a "blended model" took place, mixing on-line courses and inpresence classes. The critical increase in the number of cases since the end of the summer led to a second wave and a reinstatement of restrictions: closure of non-essential businesses (including bars and restaurants) and overnight curfew, and a second lockdown, from October 30 to December 15, 2020. After that, public policies promoted measures to reduce the transmission of Covid-19, including a curfew (until January 2021), teleworking, and remote courses in higher education institutions, until mid-2021, when vaccination was made available to the whole population.

#### Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

#### Statistical analyses

We considered the weekly number of new patients presenting at the GHU outpatient clinics, emergency department visits, and hospital admissions for all patients and by age groups. The 2020 and 2021 data were compared to the same period in 2019. The evolution of the aforementioned indicators was analysed with interrupted time-series analysis based on

negative binomial regression. The first period, defined as "pre-pandemic," was from January 1, 2019 to March 15, 2020 (T1), and the second, "since the pandemic," started the week of the first lockdown, March 17, 2020, and lasted to December 31, 2021 (T2). Seasonality was examined by introducing the week number in the regression models and was kept in the final model analysing the number of new patients at outpatient clinics and hospital admissions but did not improve model estimators for the analysis of emergency visits. Percentages of evolution were obtained by exponentiating the regression model coefficients. All statistical analyses were performed with Stata v17 (StataCorp., College Station, TX).

#### Results

#### 1. New patients attending outpatient clinics

The number of new patients attending outpatient clinics markedly decreased during 2020 as compared with 2019 (-17%) because of the pandemic and the restrictive measures taken to prevent its transmission (Figure 1; Table 1). Therefore, during the first lockdown (March-May 2020), the number of new patients decreased by 71% as compared with the same period in 2019 (Table 1). However, the number of new patients was not reduced (+8%) during the second lockdown (October-December 2020). The activity resumed in 2021 but without achieving the pre-pandemic level (-6% as compared with 2019). The number of new patients remained significantly reduced, by 9.6% (p=0.003), in T2 versus T1.

However, we observed disparities between age groups. The strongest decrease in number of new outpatients in 2020 was for the youngest patients, < 15 years old (-25%), and the oldest, > 65 years old (-25%) (Table 1). The first lockdown had a substantial impact on the number of young people attending outpatient clinics, with an 84% decrease in number of patients < 15 years old and a 72% decrease in those aged 15 to 24 years old as compared with the same period in 2019. During the second lockdown, children < 15 years showed a strong increase (+38%). After this period, outpatient consultations resumed but without reaching the 2019 level, except for the number of new patients from age 15 to 24 years, which was higher

in 2021 than 2019 (+12%). In addition, among young people (<25 years old), the number of new outpatients did not significantly decrease over the two periods, before (T1) and since the first pandemic wave (T2). Among those aged 15-24 years, the number of new outpatients increased between T1 and T2 but not significantly (+2.9%, p=0.480) (Figure 1; Table 1). For those > 25 years old, the number of new patients was significantly lower at T2 than T1. 

Age group, years	2019	2020	Evolution 2019- 2020	2021	Evolution 2019- 2021	First lockdown (March 17-May 11, 2020)	Second lockdown (Oct. 30- Dec. 15, 2020)	Comparison of T1 and T2*	P value
[0-15[	1412	1054	-25%	1362	-4%	-84%	38%	-9.7%	0.069
[15-25[	1735	1549	-11%	1949	12%	-72%	-3%	+2.9%	0.480
[25-45[	3058	2549	-17%	2813	-8%	-69%	3%	-10.4%	0.001
[45-65[	1954	1641	-16%	1645	-16%	-65%	12%	-15.6%	<0.001
[65 et +]	701	529	-25%	612	-13%	-62%	-11%	-17.2%	<0.001
All patients	8922	7363	-17%	8424	-6%	-71%	8%	-9.6%	0.003

- Table 1: Evolution of number of new patients attending the GHU outpatient clinics in 2020
- and 2021 as compared with the same period in 2019, by age groups
- T1: Jan. 1, 2019 to March 15, 2020. T2: March 16, 2020, to Dec. 31, 2021
- \*Exponentiated coefficient (p-value) from the negative binomial regression analysis
- Figure 1: Number of new patients per week attending the outpatient clinics between 2019
- and 2021

#### 2. **Emergency department visits**

Psychiatric emergency department visits decreased by 20% in 2020 compared to 2019, especially during the first lockdown (-56%) (Table 2). The number of visits decreased with increasing age, from a 58% decrease among people 15 to 24 years old to a 48% decrease among those > 65 years old. Conversely, during the second lockdown, the reduction was greater for the oldest people (-26% as compared with the same period in 2019) than for the youngest (-8%). The number of emergency visits was lower in 2021 than in 2019, except for those aged 15-24 years, with an increase of 17%. We found an increasing trend in number of

emergency visits by young adults (15-24 years old) since the beginning of 2021, which was
steeper during the second semester (Figure 2). Relative to the pre-pandemic period (T1),
emergency visits significantly decreased after the first Covid-19 wave (T2) (-9.2%, p=0.001)
for all age groups except young adults (15-24 years old), with no significant difference
between the two periods (-0.8% p=0.846) (Table 2).

Table 2: Evolution of emergency department visits in 2020 and 2021, compared to the same period in 2019, by age groups

Age group, years*	2019	2020	Evolution 2019- 2020	2021	Evolution 2019- 2021	First lockdown (March 17- May 11, 2020)	Second lockdown (Oct. 30- Dec. 15, 2020)	Comparison of T1 and T2 **	P value
[15-25[	2681	2184	-19%	3137	17%	-58%	-8%	-0.8%	0.846
[25-45[	4180	3268	-22%	3946	-6%	-57%	-7%	-11.8%	<0.001
[45-65[	2007	1644	-18%	1811	-10%	-56%	-18%	-13.7%	<0.001
[65 et +]	460	377	-18%	403	-12%	-48%	-26%	15.1%	0.006
All patients	9402	7528	-20%	9370	0%	-56%	-10%	-9.2%	0.001

<sup>184</sup> T1: Jan. 1, 2019 to March 15, 2020. T2: March 16, 2020, to Dec. 31, 2021

187 Figure 2: Number of emergency department visits per week between 2019 and 2021

### 188 3. Number of hospital admissions (full-time)

The number of hospital admissions decreased by 18% in 2020 as compared with 2019 (Table 3). The first lockdown was associated with more of a reduction (-42%) than the second lockdown (-21%). The number of admissions was lower in 2021 than 2019, except for young adults (15 to 24 years old), with a 2% increase. Between the two periods (T1 and T2), the number of hospital admissions decreased by 15.5% (p<0.001), and this reduction was significant across all age groups. Figure 3 confirms that the level of hospital admissions was lower during 2021 than in the pre-pandemic period.

Table 3: Evolution of hospital admissions (full-time) in 2020 and 2021, compared to the same period in 2019

<sup>\*</sup> Because of the small number of patients aged 0-15 years, they were not included in the analysis

<sup>\*\*</sup> Exponentiated coefficient (p-value) from the negative binomial regression analysis

Age group, years*	2019	2020	Evolution 2019- 2020	2021	Evolution 2019- 2021	First lockdown (March 17-May 11, 2020)	Second lockdown (Oct. 30- Dec. 15, 2020)	Comparison of T1 and T2 **	P value
[15-25[	2355	1987	-16%	2409	2%	-49%	-21%	-7.8%	0.004
[25-45[	5404	4345	-20%	4480	-17%	-37%	-26%	-17.9%	<0.001
[45-65[	4068	3373	-17%	3553	-13%	-40%	-11%	-14.2%	<0.001
[65 et +]	1592	1321	-17%	1296	-19%	-51%	-30%	-21.9%	<0.001
All patients	13696	11233	-18%	11988	-12%	-42%	-21%	-15.5%	<0.001

<sup>198</sup> T1: Jan. 1, 2019 to March 15, 2020. T2: March 16, 2020, to Dec. 31, 2021

Figure 3: Number of hospital admissions (full-time) per week between 2019 and 2021

#### **Discussion**

significantly in 2020 and has not yet reached its pre-pandemic level despite resuming in 2021. However, the trend was different for young adults aged 15 to 24 years, with more new outpatients (+12%), more visits to the emergency department (+17%), and more hospital admissions (+2%) in 2021 than 2019. For all other age groups, the frequency of care seeking was still lower in 2021 than 2019, especially among the oldest patients (> 65 years old).

Several French studies reported similar findings: diminished healthcare use in 2021 than in the pre-pandemic period, except for the youngest patients. In its weekly report dated

September 21, 2021, The French national public health agency (Santé Publique France) reported an increase in 2021 in number of emergency department visits for suicidal ideation and behaviour and mood disorders among children (0-17 years old) and young adults (18-24 years old) as compared with the previous 3 years. In addition, the emergency general practitioner service (SOS Médecins) reported more medical consultations for anxiety or depressive disorders among young adults in 2021 than in the previous 3 years (+30% for anxiety and +48% for depressive symptoms)[27]. Meanwhile, medical consultations for adults (> 25 years old) reached the pre-pandemic level only in July 2021. Another survey (EpiCov),

The use of mental healthcare services at the GHU Psychiatry and Neurosciences decreased

<sup>199 \*</sup> Because of the small number of patients aged 0-15 years, they were not included in the analysis

<sup>200 \*\*</sup> Exponentiated coefficient (p-value) from the negative binomial regression analysis

conducted by the French Institute of Medical Research (INSERM) and the French direction of Research, Studies, Evaluations and Statistics (DREES), reported an improvement in mental health among the general population from March 2020 to November 2020, except for young people (< 25 years old)[28]. Among them, the prevalence of depressive symptoms was still higher in November 2020 than in 2019 (+3 points for minor depressive symptoms and + 6 points for major depressive disorders) but was lower or stable for all other age groups. The situation seems to be more concerning for young women (15-24 years old), with a 23.7% prevalence of minor depressive symptoms in November 2020 but 10.7% in 2019. This survey also reported that 5.0% of participants aged 15-24 years old declared having suicidal thoughts over the past 12 months. This proportion decreased with increasing age.

This reduction in mental healthcare use in the aftermath of Covid-19–related restrictive measures was also observed in other countries. In the United Kingdom, despite a progression in number of new referrals and patients hospitalised after the lifting of lockdown (May 2020), the numbers were still substantially lower than before the pandemic[16,31]. Similarly, face-to-face contacts with community mental healthcare services remained lower than before the lockdown, several months after the lifting of restrictions. In contrast, the number of non-face-to-face contacts showed a sizeable increase, which highlights the need to assess the role of telemedicine to manage mental health disorders and monitor patients during and outside of pandemics[16,32].

Regarding the persistency of psychiatric disorders among young adults, months after the easing of Covid-19 restrictions, it seems crucial to ensure access to appropriate care and continuity of care for youth. The pandemic deeply affected the well-being of an age group already known to be vulnerable to mental health problems, as several studies reported before the Covid-19 crisis[33–36]. Adolescents and young adults have undergone many pandemic-related difficulties, with prolonged home-schooling and the need to study remotely for an entire academic year and with the closure of usual recreation areas (bars, cinemas, nightclubs etc.), not being able to have their normal social routine with friends[13]. Moreover,

restrictions led to officious festive gatherings, during which there was a higher risk of excess (substance use, risky behaviours) and potential abuse[37]. Some studies found home lockdown associated with an increase in domestic violence and ill treatment, with children more at risk in the absence of protective factors, such as access to trusted adults outside the household, school professionals, and friends[38,39].

Furthermore, disruption of care or difficulty in accessing medical care could lead to more severe presentations of psychiatric disorders or worsen pre-existing conditions. Previous work showed a resurgence of serious clinical conditions post-lockdown, including increased suicidal ideation and behaviour, and involuntary hospital admissions[20,26]. In addition, the number of suicide attempts among the youngest, including children ≤ 15 years old, has increased substantially since the end of the first Covid-19 wave as compared with previous years[40,41].

Our study was based on systematically collected medical care data provided by the GHU Psychiatry and Neurosciences facilities, over a 3-year period, covering a time before, during and after the Covid-19 pandemic. This large dataset allowed us to describe robust tendencies regarding the use of mental healthcare. Moreover, the GHU Psychiatry and Neurosciences facilities covers a large area (13 of the 20 Parisian arrondissements are linked to the GHU), so our study represents the use of care by a large sample of the population. The main limitation is the absence of information on care outside the hospital, such as private practitioners, including psychiatrists, psychologists, and general practitioners. Individuals with minor mental health problems could also have been referred to other support services, such as helplines. Furthermore, we were not able to distinguish remote medical consultations (telemedicine) from face-to-face outpatient appointments and so could not analyse the proportion of remote consultations in the activity. We need to understand these changes in providing mental health care and evaluate the therapeutic value and patient satisfaction regarding remote medical appointments.

To conclude, the Covid-19 pandemic and the associated restrictive measures used to control the spread of the virus have had severe consequences on populations' mental health, especially among young people. More worrying is the persistence of psychiatric disorders in this age group, months after the end of restrictions. Further studies are needed to assess the psychological complications associated with the Covid-19 pandemic among young people and to capture the use of mental health care to ensure that this age group benefits from appropriate care.

- **Acknowledgments**: This study used the GHU activity data, systematically recorded for any contact with a GHU medical facility. All data were completely anonymised and did not mention patients' information, expect for their age.
- Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
- **Competing interests:** None declared.
  - **Ethics approval**: French national regulation authorities do not ethics approval for the use medical and administrative information system databases. This study complied with the French Research Standards.
- 288 Patient consent for publication: Not required
- **Provenance and peer review**: Not commissioned; externally peer reviewed.
- Contributors: The study was planned by AP and VLM. Data extraction was performed by
   VLM, data analyses by AP. All authors participated to results interpretation and approved the
   final manuscript.
  - **Data sharing**: The data that support the findings are available from the corresponding author, upon reasonable request.

#### References

- 297 1 Santomauro DF, Mantilla Herrera AM, Shadid J, *et al.* Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *The Lancet* 2021;**398**:1700–12. doi:10.1016/S0140-6736(21)02143-7
- 300 2 Gloster AT, Lamnisos D, Lubenko J, *et al.* Impact of COVID-19 pandemic on mental health: An international study. *PloS One* 2020;**15**:e0244809. doi:10.1371/journal.pone.0244809
- 302 3 Bäuerle A, Teufel M, Musche V, *et al.* Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany. *J Public Health Oxf Engl* 2020;**42**:672–8. doi:10.1093/pubmed/fdaa106
- Wathelet M, Duhem S, Vaiva G, *et al.* Factors Associated With Mental Health Disorders Among University Students in France Confined During the COVID-19 Pandemic. *JAMA Netw Open* 2020;**3**:e2025591. doi:10.1001/jamanetworkopen.2020.25591
  - Glowacz F, Schmits E. Psychological distress during the COVID-19 lockdown: The young adults most at risk. *Psychiatry Res* 2020;**293**:113486. doi:10.1016/j.psychres.2020.113486
- Nearchou F, Flinn C, Niland R, *et al.* Exploring the Impact of COVID-19 on Mental Health
  Outcomes in Children and Adolescents: A Systematic Review. *Int J Environ Res Public Health*2020;**17**:E8479. doi:10.3390/ijerph17228479
- 7 Pierce M, Hope H, Ford T, *et al.* Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. *Lancet Psychiatry* 2020;**7**:883–92. doi:10.1016/S2215-0366(20)30308-4
- Meherali S, Punjani N, Louie-Poon S, *et al.* Mental Health of Children and Adolescents Amidst COVID-19 and Past Pandemics: A Rapid Systematic Review. *Int J Environ Res Public Health* 2021;**18**:3432. doi:10.3390/ijerph18073432
- Tackling the mental health impact of the COVID-19 crisis: An integrated, whole-of-society response. OECD. May 2021. https://www.oecd.org/coronavirus/policy-responses/tackling-the-mental-health-impact-of-the-covid-19-crisis-an-integrated-whole-of-society-response-0ccafa0b/ (accessed 20 Oct 2021).
- 10 Fancourt D, Steptoe A, Bu F. Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study. *Lancet Psychiatry* 2021;**8**:141–9. doi:10.1016/S2215-0366(20)30482-X
- Macalli M, Texier N, Schück S, *et al.* A repeated cross-sectional analysis assessing mental health conditions of adults as per student status during key periods of the COVID-19 epidemic in France. *Sci Rep* 2021;**11**:21455. doi:10.1038/s41598-021-00471-8
- 329 12 Bulloch A, Zulyniak S, Williams J, *et al.* Poor Mental Health during the COVD-19 Pandemic: Effect Modification by Age. *Can J Psychiatry Rev Can Psychiatr* 2021;**66**:827–9. doi:10.1177/0706743721994408
- 332 13 Mohler-Kuo M, Dzemaili S, Foster S, *et al.* Stress and Mental Health among
  333 Children/Adolescents, Their Parents, and Young Adults during the First COVID-19 Lockdown in
  334 Switzerland. *Int J Environ Res Public Health* 2021;**18**:4668. doi:10.3390/ijerph18094668
- Mengin A, Allé MC, Rolling J, *et al.* [Psychopathological consequences of confinement].
   *L'Encephale* 2020;46:S43–52. doi:10.1016/j.encep.2020.04.007
- 337 15 Gómez-Ramiro M, Fico G, Anmella G, *et al.* Changing trends in psychiatric emergency service admissions during the COVID-19 outbreak: Report from a worldwide epicentre. *J Affect Disord* 2021;**282**:26–32. doi:10.1016/j.jad.2020.12.057

340 341 342	16	Bakolis I, Stewart R, Baldwin D, <i>et al.</i> Changes in daily mental health service use and mortality at the commencement and lifting of COVID-19 "lockdown" policy in 10 UK sites: a regression discontinuity in time design. <i>BMJ Open</i> 2021; <b>11</b> :e049721. doi:10.1136/bmjopen-2021-049721
343 344 345	17	Seo JH, Kim SJ, Lee M, <i>et al.</i> Impact of the COVID-19 pandemic on mental health service use among psychiatric outpatients in a tertiary hospital. <i>J Affect Disord</i> 2021; <b>290</b> :279–83. doi:10.1016/j.jad.2021.04.070
346 347 348	18	Dragovic M, Pascu V, Hall T, <i>et al.</i> Emergency department mental health presentations before and during the COVID-19 outbreak in Western Australia. <i>Australas Psychiatry Bull R Aust N Z Coll Psychiatr</i> 2020; <b>28</b> :627–31. doi:10.1177/1039856220960673
349 350 351	19	Zielasek J, Vrinssen J, Gouzoulis-Mayfrank E. Utilization of Inpatient Mental Health Care in the Rhineland During the COVID-19 Pandemic. <i>Front Public Health</i> 2021; <b>9</b> :212. doi:10.3389/fpubh.2021.593307
352 353 354	20	Ambrosetti J, Macheret L, Folliet A, <i>et al.</i> Psychiatric emergency admissions during and after COVID-19 lockdown: short-term impact and long-term implications on mental health. <i>BMC Psychiatry</i> 2021; <b>21</b> :465. doi:10.1186/s12888-021-03469-8
355 356 357	21	Pignon B, Gourevitch R, Tebeka S, <i>et al.</i> Dramatic reduction of psychiatric emergency consultations during lockdown linked to COVID-19 in Paris and suburbs. <i>Psychiatry Clin Neurosci</i> 2020; <b>74</b> :557–9. doi:10.1111/pcn.13104
358 359 360	22	Pham-Scottez A, Silva J, Barruel D, <i>et al.</i> Patient flow in the largest French psychiatric emergency centre in the context of the COVID-19 pandemic. <i>Psychiatry Res</i> 2020; <b>291</b> :113205. doi:10.1016/j.psychres.2020.113205
361 362 363	23	The impact of COVID-19 on mental, neurological and substance use services: results of a rapid assessment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO https://www.who.int/publications-detail-redirect/978924012455 (accessed 29 Oct 2021).
364 365 366	24	Brooks SK, Webster RK, Smith LE, <i>et al.</i> The psychological impact of quarantine and how to reduce it: rapid review of the evidence. <i>The Lancet</i> 2020; <b>395</b> :912–20. doi:10.1016/S0140-6736(20)30460-8
367 368 369	25	Chen S, She R, Qin P, et al. The Medium-Term Impact of COVID-19 Lockdown on Referrals to Secondary Care Mental Health Services: A Controlled Interrupted Time Series Study. Front Psychiatry 2020;11:1307. doi:10.3389/fpsyt.2020.585915
370 371 372	26	O'Connor RC, Wetherall K, Cleare S, <i>et al.</i> Mental health and well-being during the COVID-19 pandemic: longitudinal analyses of adults in the UK COVID-19 Mental Health & Wellbeing study. <i>Br J Psychiatry</i> 2021; <b>218</b> :326–33. doi:10.1192/bjp.2020.212
373 374	27	Analyse hebdomadaire des indicateurs surveillés en continu. Santé Publique France. POINT ÉPIDÉMIO – Santé mentale. Édition nationale mensuelle n°1. 21/09 /2021
375 376 377 378 379	28	Une dégradation de la santé mentale chez les jeunes en 2020. Résultats issus de la 2e vague de l'enquête EpiCov. Direction de la Recherche, des Etudes, de l'Evaluation et des lStatistiques (DREES). Octobre 2021. Numéro 1210. https://drees.solidarites-sante.gouv.fr/publications/etudes-et-resultats/une-degradation-de-la-sante-mentale-chez-les-jeunes-en-2020 (accessed 18 Mar 2022).
380 381	29	Berete F, Braekman E, Bruggeman H, <i>et al.</i> Sixième enquête de santé COVID-19 : résultats

30 Coronavirus and depression in adults, Great Britain. Office for National Statistics. 18 August 2020.

https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/articles/coronavirusanddepress

préliminaires. Sciensano 2021. doi:10.25608/J877-KF56

ioninadultsgreatbritain/june2020 (accessed 10 Nov 2021).

- 385 31 Howarth A, Munro M, Theodorou A, *et al.* Trends in healthcare utilisation during COVID-19: a longitudinal study from the UK. *BMJ Open* 2021;**11**:e048151. doi:10.1136/bmjopen-2020-048151
- 32 Chen S, Jones PB, Underwood BR, *et al.* The early impact of COVID-19 on mental health and community physical health services and their patients' mortality in Cambridgeshire and Peterborough, UK. *J Psychiatr Res* 2020;**131**:244–54. doi:10.1016/j.jpsychires.2020.09.020
- 39 Auerbach RP, Mortier P, Bruffaerts R, *et al.* WHO World Mental Health Surveys International College Student Project: Prevalence and distribution of mental disorders. *J Abnorm Psychol* 2018;**127**:623–38. doi:10.1037/abn0000362
- 393 34 Mojtabai R, Olfson M, Han B. National Trends in the Prevalence and Treatment of Depression in Adolescents and Young Adults. *Pediatrics* 2016;**138**:e20161878. doi:10.1542/peds.2016-1878
- 35 Ivey-Stephenson AZ, Demissie Z, Crosby AE, *et al.* Suicidal Ideation and Behaviors Among High 396 School Students - Youth Risk Behavior Survey, United States, 2019. *MMWR Suppl* 2020;**69**:47– 397 55. doi:10.15585/mmwr.su6901a6
- 36 Hertz MF, Barrios LC. Adolescent mental health, COVID-19, and the value of school-community partnerships. *Inj Prev J Int Soc Child Adolesc Inj Prev* 2021;**27**:85–6. doi:10.1136/injuryprev-2020-
- 401 37 Peraud W, Quintard B, Constant A. Factors associated with violence against women following the
   402 COVID-19 lockdown in France: Results from a prospective online survey. *PLOS ONE* 403 2021;**16**:e0257193. doi:10.1371/journal.pone.0257193
- 404 38 Augusti E-M, Sætren SS, Hafstad GS. Violence and abuse experiences and associated risk 405 factors during the COVID-19 outbreak in a population-based sample of Norwegian adolescents. *Child Abuse Negl* 2021;**118**:105156. doi:10.1016/j.chiabu.2021.105156
- 407 39 Pannizzotto S, Depuis Z, Frère J, *et al.* [Impact of COVID-19 outbreak on domestic violence and child abuse]. *Rev Med Liege* 2021;**76**:789–93.
- 409 40 Cousien A, Acquaviva E, Kernéis S, *et al.* Temporal Trends in Suicide Attempts Among Children 410 in the Decade Before and During the COVID-19 Pandemic in Paris, France. *JAMA Netw Open* 411 2021;**4**:e2128611. doi:10.1001/jamanetworkopen.2021.28611
  - 41 Yard E, Radhakrishnan L, Ballesteros MF, et al. Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12-25 Years Before and During the COVID-19 Pandemic United States, January 2019-May 2021. MMWR Morb Mortal Wkly Rep 2021;70:888–94. doi:10.15585/mmwr.mm7024e1

#### Figure legend:

- Note: The weeks of the first (March 17 to May 11, 2020) and second (Oct. 30 to Dec. 15,
- 2020) lockdowns are presented on the graph in orange and yellow, respectively
- Figure 1: Number of new patients per week attending the GHU outpatient clinics between
- 2019 and 2021. All new patients on the left and new patients aged 15-24 years old on the
- right.

- Figure 2: Number of emergency department visits per week between 2019 and 2021. All
- patients on the left and patients aged 15-24 years old on the right.
- Figure 3: Number of hospital admissions (full-time) per week between 2019 and 2021. All
- patients on the left and patients aged 15-24 years old on the right.






Figure 1: Number of new patients per week attending the GHU outpatient clinics between 2019 and 2021.

All new patients on the left and new patients aged 15-24 years old on the right.

317x147mm (96 x 96 DPI)




Figure 2: Number of emergency department visits per week between 2019 and 2021. All patients on the left and patients aged 15-24 years old on the right.

317x147mm (96 x 96 DPI)




Figure 3: Number of hospital admissions (full-time) per week between 2019 and 2021. All patients on the left and patients aged 15-24 years old on the right.

317x147mm (96 x 96 DPI)

 The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items  RECORD items  964 975 975 975 975 975	Location in manuscript where items are reported
Title and abstra	ct			Те ер	
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 1	RECORD 1.1: The type of that used should be specified in the title or abstract. When possible, the mame of the databases used should be included.  RECORD 1.2: If applicable the geographic region and time that within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Page 1-2
Introduction	1			7/0	
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4	on April 10	
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5	, 2024 by (	
Methods				guest.	
Study Design	4	Present key elements of study design early in the paper	Page 5	st. Prot	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 5-6	Protected by copyright	

Participants	6	(a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and	Page 5	RECORD 6.1: The methods of study population selection (such a scodes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.  RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage	NA
		and number of exposed and unexposed  Case-control study - For matched studies, give matching criteria and the number of controls per case	'evie	process, including the number of individuals with linked data at each stage.	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	Page 6	RECORD 7.1: A complete lest of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.	NA
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group	Page 6	guest. Protected by copyright	

Bias	9	Describe any efforts to address potential sources of bias	NA	pen-20	
Study size	10	Explain how the study size was arrived at	NA	22-064:	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	Page 6	305 on 23 Februa	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) Cohort study - If applicable, explain how loss to follow-up was addressed Case-control study - If applicable, explain how matching of cases and controls was addressed Cross-sectional study - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	Page 6-7	ppen-2022-064305 on 23 February 2023. Downloaded from http://bmjopen.bmj.com/ on April 10, 2024 by	
Data access and cleaning methods				RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	Page 5

			RECORD 12.2: Authors should	
			provide information on the data	
			cleaning methods used in the study.	
			RECORD 12.3: State whether the	NA
			study included person-level.	
1			202	
13	(a) Report the numbers of	NA	RECORD 13.1: Describe in detail the	
	` '			
			-	
		V <sub>L</sub>		
		1		
	1		<u> </u>	
	, , ,	<b>C</b> 1	gnjo	
			per	
	` '	10	ı.bm	
14		NA	3.00	
	, ,		/mc	
			on	
			Apri	
	confounders		110	
	(b) Indicate the number of		3, 20	
	` /		024	
	for each variable of interest		by	
	(c) Cohort study - summarise		gue	
			yst.	
	1			
15	Cohort study - Report numbers	Page 8-9-10	<u>ਓ</u> ਨੂੰ	
	of outcome events or summary		ed =	
	measures over time		у с	
	Case-control study - Report		) p)	
1	numbers in each exposure		<u>)</u>	
		(a) Report the numbers of individuals at each stage of the study (e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram  (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) Cohort study - summarise follow-up time (e.g., average and total amount)  15 Cohort study - Report numbers of outcome events or summary measures over time  Case-control study - Report	13 (a) Report the numbers of individuals at each stage of the study (e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram  14 (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) Cohort study - summarise follow-up time (e.g., average and total amount)  15 Cohort study - Report numbers of outcome events or summary measures over time Case-control study - Report	Described information on the data cleaning methods used in the study.

	-		1	7	
		category, or summary measures of exposure Cross-sectional study - Report numbers of outcome events or		pen-2022-064305	
Main results	16	summary measures (a) Give unadjusted estimates	NA		
		and, if applicable, confounder- adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period		on 23 February 2023. Downloaded from http://bmjopen.bmj.cc	
Other analyses	17	Report other analyses done—	Page 8-9-10	bmjc	
		e.g., analyses of subgroups and interactions, and sensitivity analyses	(0)	pen.bmj.cc	
Discussion				T)	
Key results	18	Summarise key results with reference to study objectives	Page 10	on Apri	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.  Discuss both direction and magnitude of any potential bias		RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Page 12
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	Page 11	by copyright.	

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence		open-2022-064:	
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 12	305 on 23	
Other Information	n			Te B	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 13	ruary 2023. Dowr	
Accessibility of protocol, raw data, and programming code			2/ /	RECORD 22.1: Authors should provide information on hower access any supplemental information such as the study protocol, raw data or programming code.	Page 13

\*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langen SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Medicine 2015; in press. omj.com/ on April 10, 2024 by guest. Protected by copyright.

\*Checklist is protected under Creative Commons Attribution (CC BY) license.

## **BMJ Open**

# Use of mental health services in the aftermath of Covid-19 waves: a retrospective study conducted in a French Psychiatric & Neurosciences University Hospital.

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-064305.R1
Article Type:	Original research
Date Submitted by the Author:	29-Nov-2022
Complete List of Authors:	PEROZZIELLO, Anne; Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences, Cellule épidémiologie SOUSA, Daniel; Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences, Département d'Information Médicale AUBRIOT, Béatrice; Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences DAURIAC-LE MASSON, Valérie; Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences
<b>Primary Subject Heading</b> :	Epidemiology
Secondary Subject Heading:	Mental health, Health services research
Keywords:	MENTAL HEALTH, PSYCHIATRY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, COVID-19

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

- 1 Use of mental health services in the aftermath of Covid-19 waves: a retrospective
- 2 study conducted in a French Psychiatric & Neurosciences University Hospital.
- Anne Perozziello<sup>1</sup>, Daniel Sousa<sup>2</sup>, Béatrice Aubriot<sup>3</sup>, Valerie Dauriac-Le Masson<sup>2</sup>
- 4 ¹ Cellule épidémiologie, GHU Paris Psychiatrie & Neurosciences
- 5 <sup>2</sup> Département d'Information Médicale, GHU Paris Psychiatrie & Neurosciences
- 6 <sup>3</sup> Commission Médicale d'Etablissement, GHU Paris Psychiatrie & Neurosciences
- 7 Corresponding author: Anne PEROZZIELLO GHU Paris Psychiatrie et Neurosciences 1
- 8 rue Cabanis, 75014 PARIS <u>a.perozziello@ghu-paris.fr</u>
- 9 Word count: 4072
- 10 Keywords: mental health; COVID-19; psychiatry; health services use; young adults
- 11 Abstract (296 words)
- **Objective**: The Covid-19 pandemic and the restrictive measures taken to prevent its
- propagation had profound effects on mental health and well-being, especially in children and
- 14 young adults (< 25 years old). This study aimed to analyse the medium and long-term impact
- of the Covid-19 pandemic on the use of the mental health services, by age groups and
- 16 gender.
- **Design:** We conducted a retrospective study using the medical and administrative
- information system databases of patients, between 2019 and 2021.
- **Setting**: This study was conducted in the Groupe Hospitalier Universitaire (GHU) Paris
- 20 Psychiatry and Neurosciences.
- **Outcome measures**: We reported three indicators: the number of new patients attending
- outpatient clinics, the number of emergency department (ED) visits, and the number of
- 23 hospital admissions.

- Methods: We considered the weekly number of each indicator, by age groups and by
  gender. We also collected the reasons of ED visits and hospital admissions. The 2020 and
  2021 data were compared to the same period in 2019. The evolution of the indicators over
  the 3 years was analysed with interrupted time-series analysis.
- Results: All three indicators showed a dramatic decrease during the first lockdown period

  (March 2020) especially for the youngest. In 2021, the activity resumed but without reaching

  its pre-pandemic level. Moreover, mental health care seeking was significantly lower since

  the beginning of the pandemic compared to the pre-pandemic period for all age groups,

  except for young women (< 25 years old). Among them, there was a higher level of mental

  health services use in 2021, compared to 2019: +20% of new patients at the outpatient

  clinics, +39% of ED visits, and +17% of hospital admissions.
  - **Conclusions**: The Covid-19 pandemic has had severe consequences on populations' mental health, especially among young women, which seem to persist months after the end of restrictive measures.

#### Strengths and limitation of this study

- Our study was based on a large dataset of systematically collected medical care data over a 3-year period, allowing us to describe tendencies on time before, during and after the Covid-19 pandemic.
- The GHU Psychiatry and Neurosciences facilities cover a large area (13 of the 20
  Parisian arrondissements are linked to the GHU), so our study sample represents the
  use of mental healthcare services by the Parisian population.
- The main limitation is the absence of information on care outside the hospital, such
  as private practitioners, including psychiatrists, psychologists, and general
  practitioners, or other support services, such as helplines.

From our data, we were not able to distinguish remote medical consultations
(telemedicine) from face-to-face outpatient appointments and so could not analyse
the proportion of remote consultations in the activity.



#### Context

The Covid-19 pandemic and the restrictive measures taken to prevent its propagation (lockdown, curfews, quarantines, movement restrictions etc.) were associated with increased prevalence of major depressive symptoms and anxiety disorders[1–3]. Fear of infection, social media and news exposure, and the consequences of the lockdown (boredom, social isolation, stress, sleeping disorders, pandemic-related uncertainty, loneliness etc.) have had detrimental effects on the mental health and well-being among the population. These effects were more pronounced in some groups, especially children and young adults (< 25 years old)[4–8]. Several studies reported a higher prevalence of mental health problems in young people than older adults[1,9–13]. School and university closures, lack of social interactions and activities, and for students, being confined in small or uncomfortable spaces, away from their families, have worsened the negative effect of Covid-19 on mental health[1,8,14]. In the meantime, the pandemic and the unprecedented measures decided in many countries have led to a drastic decrease in contacts with mental healthcare systems[15–20]. In France, two studies showed a sharp reduction in emergency department (ED) visits. The first study, conducted in three psychiatric ED in Paris and its suburbs, estimated that during the first weeks of the first lockdown in France (March 17 to May 11, 2020), the number of visits decreased by 54.8% as compared with the same period in 2019[21]. This decrease was statistically significant for the 16-24 years old (-64.4%). The study by Pham et al. analysed the activity of one of the largest Parisian psychiatric ED, reporting a significant reduction in visits during the first lockdown as compared with the same period in 2019 (10.8 consultations a day vs 26.4 in 2019)[22]. The authors suggested that patients might have avoided hospitals because of fear of being infected or being sanctioned for not complying with movement restrictions. Moreover, the entire healthcare system was disrupted during the first months of the pandemic, with reduced access to medical facilities and prioritised admissions for severe cases[23].

Therefore, patients faced difficulties accessing appropriate care during this period, which raised fears of a possible psychiatric outbreak post-lockdown and a strong increase in care needs[14,24]. However, despite the lifting of containment measures, the use of healthcare services has returned to pre-pandemic levels, with no substantial increase[25]. Several studies demonstrated an improvement in mental health among the general population after the lifting of the lockdown and a decrease in anxiety and depressive disorders[10,26]. Yet, these findings do not apply evenly across age groups. After intensely experiencing the adverse effects of the lockdown, young people showed persistent depressive and anxiety symptoms and suicidal ideation etc., months after the easing of most restrictions related to Covid-19[26–29].

At the Groupe Hospitalier Universitaire (GHU) Psychiatry and Neurosciences in Paris, a drastic reduction in mental health services use was reported during the first lockdown period, in spring 2020. However, few studies analysed the medium and long-term impact of the Covid-19 pandemic on mental health care use. This study analysed the use of the GHU mental healthcare services between 2019 and 2021, comparing the period before and the period after the "first wave" of Covid-19 (March 2020) for all patients, by age groups and by gender. We also described reasons of ED visits and hospital admissions over the period.

#### Material and methods

We conducted a retrospective study of data collected from the GHU medical and administrative information system, which includes inpatients' discharge summaries and outpatients' visits for all patients presenting at one of the GHU medical facilities. The GHU Psychiatry and Neurosciences in Paris is the main provider of mental healthcare in the Paris area, with 170 medical services. The GHU represents a catchment area of 1.6 million Parisians.

Patient data are systematically collected in electronic medical records. The physician in charge of the information system extracted weekly data from January 1, 2019 to December

31, 2021 for all patients without exclusion. We analysed data on the number of new patients at the outpatient clinic, number of visits to the ED, and number of hospital admissions (full-time), summarised by age groups, by gender and by diagnosis categories from the International Classification of Diseases 10th Revision (ICD-10) for psychiatric disorders. Suicidal ideation and suicide attempts were identified separately, by year, as the number of events per week was low. Non-psychiatric diagnoses (symptoms, health hazards, etc.) were grouped under a different category.

The first wave of the Covid-19 pandemic in France started in March 2020. During the first lockdown, from March 17 to May 11, 2020, the government imposed a mandatory home lockdown, with strict restrictions on movement outside the household. Schools and universities as well as non-essential public places, including restaurants, cafés, and cinemas, were closed. On May 11, the lockdown ended, but some measures remained to control the spread of the virus. Social distancing, compulsory mask-wearing (indoor and outdoor), limitations on gatherings, overnight curfew, and teleworking was supported when possible. Primary and middle schools reopened, but high schools and universities remained closed until September 2020, when a "blended model" took place, mixing on-line courses and inpresence classes. The critical increase in the number of cases since the end of the summer led to a second wave and a reinstatement of restrictions: closure of non-essential businesses (including bars and restaurants) and overnight curfew, and a second lockdown, from October 30 to December 15, 2020. After that, public policies promoted measures to reduce the transmission of Covid-19, including a curfew (until January 2021), teleworking, and remote courses in higher education institutions, until mid-2021, when vaccination was made available to the whole population.

#### Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

### Statistical analyses

We considered the weekly number of new patients presenting at the GHU outpatient clinics, ED visits, and hospital admissions for all patients, by age groups, by gender and diagnoses for ED visits and hospital admissions. The 2020 and 2021 data were compared to the same period in 2019. The evolution of the aforementioned indicators was analysed with interrupted time-series analysis based on negative binomial regression. The first period, defined as "prepandemic," was from January 1, 2019 to March 15, 2020 (T1), and the second, "since the pandemic," started the week of the first lockdown, March 17, 2020, and lasted to December 31, 2021 (T2). Seasonality was examined by introducing the week number in the regression models and was kept in the final model analysing the number of new patients at outpatient clinics and hospital admissions but did not improve model estimators for the analysis of ED visits. Percentages of evolution were obtained by exponentiating the regression model coefficients. We also described weekly evolution of reasons of ED visits and hospital admissions by disease categories. All statistical analyses were performed with Stata v17 (StataCorp., College Station, TX).

#### Results

## 1. New patients attending outpatient clinics

The number of new patients attending outpatient clinics markedly decreased during 2020 as compared with 2019 (-17%) because of the pandemic and the restrictive measures taken to prevent its transmission (Figure 1; Table 1). Therefore, during the first lockdown (March-May 2020), the number of new patients decreased by 71% as compared with the same period in 2019 (Table 1). However, the number of new patients was not reduced (+8%) during the second lockdown (October-December 2020). The activity resumed in 2021 but without achieving the pre-pandemic level (-6% as compared with 2019). The number of new patients remained significantly reduced, by 9.6% (p=0.003), in T2 versus T1.

However, we observed disparities between age groups. The strongest decrease in number of new outpatients in 2020 was for the youngest patients, under 15 years of age (-25%), and the oldest, > 65 years old (-25%) (Table 1). The first lockdown had a substantial impact on the number of young people attending outpatient clinics, with an 84% decrease in number of patients aged under 15 years and a 72% decrease in those aged 15 to 24 years old as compared with the same period in 2019. During the second lockdown, children < 15 years showed a strong increase (+38%) as well as young women aged 15 to 24 years old (+9%). After this period, outpatient consultations resumed but without reaching the 2019 level, except for the number of girls under 15 (+6% in 2021 as compared with 2019) and patients from age 15 to 24 years, with +20% of young women presenting for the first time at the clinics and +4% of young men (Figure 2). In addition, among young people (<25 years old), the number of new outpatients did not significantly decrease over the two periods, before (T1) and since the first pandemic wave (T2), with even an increase of new outpatients among young women (aged 15-24 years), but not statistically significant (+8.1%, p=0.082).( Table 1). For those > 25 years old, the number of new patients was significantly lower at T2 than T1.

Table 1: Evolution of the number of contacts with mental healthcare services provided by the GHU Psychiatry and Neuroscience in 2020 and 2021, as compared with the same period in 2019, by age groups and gender

45 46	Number of new patients attending the GHU outpatient clinics												
47 Age group, years	2019	2020	Evolution	2021	Evolution	First	Second	Comparison	P				
48			2019-		2019-	lockdown	lockdown	of T1 and	value				
49			2020		2021	(March 1- May 11,	(Oct. 30- Dec. 15,	T2*					
50 51						2020)	2020)						
52 0-14	1412	1054	-25%	1362	-4%	-84%	38%	-9.7%	0.069				
5B 0-14 women	463 (33%)	356 (34%)	-23%	490 (36%)	6%	-72%	19%	-0.7%	0.908				
5 <del>4</del> 0-14 men	949 (67%)	698 (66%)	-26%	872 (64%)	-8%	-89%	52%	-14.3%	0.014				
55 15-24	1735	1549	-11%	1949	12%	-72%	-3%	+2.9%	0.480				
56 57 15-24 women	928 (53%)	883 (57%)	-5%	1109 (57%)	20%	-72%	9%	8.1%	0.082				
58 <sup>15-25</sup> men	807 (47%)	666 (43%)	-17%	840 (43%)	4%	-72%	-15%	-2.8%	0.526				
59 25-44	3058	2549	-17%	2813	-8%	-69%	3%	-10.4%	0.001				
60 25-44 women	1600 (52%)	1276 (50%)	-20%	1378 (49%)	-14%	-70%	-11%	-15.0%	< 0.001				

2									
3 25-44 men	1458 (48%)	1273 (50%)	-13%	1435 (51%)	-2%	-67%	21%	-5.5%	0.133
4 45-64	1954	1641	-16%	1645	-16%	-65%	12%	-15.6%	<0.001
5 45-64 women	1062 (54%)	885 (54%)	-17%	842 (51%)	-21%	-67%	9%	-19.2%	< 0.001
6 45-64 men	892 (46%)	756 (46%)	-15%	803 (49%)	-10%	-63%	15%	-11.1%	0.006
8 65 et +	701	529	-25%	612	-13%	-62%	-11%	-17.2%	<0.001
9 65 et + women	1062 (64%)	885 (67%)	-17%	842 (61%)	-21%	-64%	-7%	-17.2%	0.004
10 65 et + men	447 (36%)	352 (33%)	-21%	371 (39%)	-17%	-59%	-17%	-17.5%	0.011
1 All patients	8922	7363	-17%	8424	-6%	-71%	8%	-9.6%	0.003
12 All patients women	4540 (51%)	3774 (51%)	-17%	4215 (50%)	-7%	-69%	2%	-10.3%	< 0.001
All patients men	4382 (49%)	3589 (49%)	-18%	4209 (50%)	-4%	-72%	15%	-8.8%	0.013
15		1	Number of e	mergency dep	oartment vis	its			
15 Age group, years* 17 18 19	2019	2020	Evolution 2019- 2020	2021	Evolution 2019- 2021	First lockdown (March 17-May	Second lockdown (Oct. 30- Dec. 15,	Comparison of T1 and T2 **	P value
20 21 15-24	2681	2184	-19%	3137	17%	11, 2020)	2020) -8%	-0.8%	0.846
21 15-24 22 15-24 women	1313 (49%)	1086 (50%)	-19% -17%	1825 (58%)	39%	-58% -64%	-8% -9%	- <b>0.8%</b> 12.7%	0.846
23 <i>15-25 men</i>	, ,	' '	-20%	, ,	-4%	-52%	-9% -7%	-13.7%	< 0.032
24 25-44	1368 (51%) 4180	1098 (50%) <b>3268</b>	-20% -22%	1312 (42%) 3946	-4% - <b>6%</b>	-52% -57%	-7% -7%	-13.7%	<0.001
25-44 women		1320 (40%)		1633 (41%)	-3%				0.001
26	1683 (40%)	` ′	-22%	` ′		-52%	-10%	-10.6%	
27 25-44 men	2497 (60%) 2007	1948 60%) <b>1644</b>	-22% -18%	2313 (59%) 1811	-7% - <b>10%</b>	-60% -56%	-4%	-12.6%	<0.001 <0.001
28 45-64							-18%	-13.7%	
29 45-64 women	928 (46%)	714 (43%)	-23%	869 (48%)	-6%	-58%	-16%	-13.9%	0.001
30 45-64 men 31 65 et +	1079 (54%)	930 (57%)	-14%	942 (48%)	-13%	-55%	-19%	-13.6%	0.001
29	460	377	-18%	403	-12% -12%	-48%	-26%	-15.1%	0.006
38 65 et + women	279 (61%)	233 (62%)	-16%	245 (61%)		-51%	-17%	-16.0%	0.020
34 65 et + men	181 (39%)	144 (38%)	-20%	158 (39%)	-13%	-42%	-41%	-13.6%	0.118
35 All patients	9402	7528	-20%	9370	0%	-56%	-10%	-9.2%	0.001
36 All patients women	4245 (45%)	3382 (45%)	-20%	4611 (49%)	9%	-57%	-12%	-4.4%	0.195
37 All patients men 38	5157 (55%)	4146 (55%)	-20%	4759 (51%)	-8%	-56%	-9%	-13.1%	< 0.001
39			Number	of hospital ac	dmissions				
40 Age group, years* 41 42 43	2019	2020	Evolution 2019- 2020	2021	Evolution 2019- 2021	First lockdown (March 17-May 11, 2020)	Second lockdown (Oct. 30- Dec. 15, 2020)	Comparison of T1 and T2 **	P value
45 15-24	2355	1987	-16%	2409	2%	-49%	-21%	-7.8%	0.004
46 15-24 women	1104 (47%)	850 (43%)	-23%	1289 (54%)	17%	-58%	-25%	-1.0%	0.807
47 15-25 men	1251 (53%)	1137 (57%)	-9%	1120 (46%)	-10%	-40%	-18%	-13.6%	< 0.001
48 25-44 49	5404	4345	-20%	4480	-17%	-37%	-26%	-17.9%	<0.001
50 <sup>25-44</sup> women	2127 (39%)	1710 (39%)	-20%	1830 (41%)	-14%	-42%	-18%	-16.5%	< 0.001
51 25-44 men	3277 (61%)	2635 (61%)	-20%	2650 (59%)	-19%	-34%	-31%	-18.7%	< 0.001
52 45-64	4068	3373	-17%	3553	-13%	-40%	-11%	-14.2%	<0.001
58 54 <i>45-64 women</i>	1984 (49%)	1584 (47%)	-20%	1732 (49%)	-13%	-42%	-8%	-16.1%	< 0.001
55 45-64 men	2084 (51%)	1789 (53%)	-14%	1821 (51%)	-13%	-37%	-13%	-12.5%	< 0.001
56 65 et +	1592	1321	-17%	1296	-19%	-51%	-30%	-21.9%	<0.001
57 65 et + women	969 (61%)	834 (63%)	-14%	824 (64%)	-15%	-47%	-30%	-19.0%	< 0.001
58 59 65 et + men	623 (39%)	487 (37%)	-22%	472 (36%)	-24%	-58%	-29%	-26.5%	< 0.001
60 All natients	13696			11988		-42%	-21%	-15 5%	<0.001

-15.5%

<0.001

-21%

-42%

11988

-12%

-18%

11233

13696

60 All patients

- 3	All patients women	6319 (46%)	5079 (45%)	-20%	5806 (48%)	-8%	-46%	-19%	-14.1%	< 0.001
4	All patients men	7377 (54%)	6154 (55%)	-17%	6182 (52%)	-16%	-38%	-23%	-16.6%	< 0.001

<sup>175</sup> T1: Jan. 1, 2019 to March 15, 2020. T2: March 16, 2020, to Dec. 31, 2021

Figure 2: Number of healthcare contacts per week, between 2019 and 2021, for patients aged 15-24 years old

### Emergency department visits

Psychiatric ED visits decreased by 20% in 2020 compared to 2019, especially during the first lockdown (-56%) (Table 1) when the number of visits decreased with increasing age, from a 58% decrease among people 15 to 24 years old to a 48% decrease among those > 65 years old. Conversely, during the second lockdown, the reduction was greater for the oldest people (-26% as compared with the same period in 2019) than for the youngest (-8%). The number of ED visits was lower in 2021 than in 2019, except for women aged 15-24 years, with an increase of 39%. As shown on figure 2, there was an increasing trend in number of ED visits by young adults (15-24 years old) since the beginning of 2021, which was steeper during the second semester. Relative to the pre-pandemic period (T1), emergency visits significantly decreased after the first Covid-19 wave (T2) (-9.2%, p=0.001) for all age groups except among young women (15-24 years old), with a significant increase between the two periods (+12.7%% p=0.032) (Table 1).ED visits for neurotic disorders increased in all age groups between 2019 and 2021 (supplementary material 1) and among young adults (15-24 years old), visits related to mood disorders strongly increased between 2019 and 2021 (+44%) (figure 3). Disorders due to psychoactive substances use only increased among patients under 45 years old (+10% among 15-24 years old and +4% among 25-44 years old). In reverse, ED visits for schizophrenic and personality disorders were lower in 2021 compared to 2019 in all age groups. Visits due to suicidal ideations or suicide attempts made by young adults slightly increased in 2021 compared with 2019 (+18%, data not shown) but this figure must be interpreted cautiously as the frequency of events was very low.

<sup>\*</sup> Because of the small number of patients aged 0-15 years, they were not included in the analysis

<sup>\*\*</sup> Exponentiated coefficient (p-value) from the negative binomial regression analysis

Figure 3: Number of healthcare contacts per week, between 2019 and 2021, for mood disorders among patients aged 15-24 years old.

#### 3. <u>Number of hospital admissions (full-time)</u>

The number of hospital admissions decreased by 18% in 2020 as compared with 2019 (Table 1). The first lockdown was associated with more of a reduction (-42%) than the second lockdown (-21%). The number of admissions was lower in 2021 than 2019, except for young women (15 to 24 years old), with a 17% increase. Between the two periods (T1 and T2), the number of hospital admissions decreased by 15.5% (p<0.001), and this reduction was significant across all age groups, but not for young women (15 to 24 years old) with almost no difference in the number of hospital admissions between T1 and T2 (-1.0%, p=0.807). Hospital admissions decreased steeply for the oldest (+65 years old) with more than a quarter less admissions in T2 compared to T1 among men in this age group (-26.5%). Figure 1 confirms that the level of hospital admissions was lower during 2021 than in the prepandemic period. Regarding reasons of hospital admissions, there was an increase between 2019 and 2021 of mood disorders in all age groups except among the oldest (65 years old and over) (supplementary material 2) (Figure 3) while the number of hospital admissions related to schizophrenia was lower in 2021 compared to 2019 in all age groups. There was also a strong increase (+20%) of young adults (15-24 years old) admitted for disorders related to substance use disorders. In reverse, admissions for suicidal ideation or attempted suicides of young aged 15-24 were lower in 2020 and 2021, compared to 2019 (-25% and -8%, data not shown).

## **Discussion**

The use of mental healthcare services at the GHU Psychiatry and Neurosciences decreased significantly in 2020 and has not yet reached its pre-pandemic level despite resuming in

2021. However, the trend was different for young women aged 15 to 24 years, with a strong increase in mental health services use: +20% of new outpatients, +39% of visits to the ED and +17% of hospital admissions in 2021 as compared with 2019. There was also an increase in the number of young men presenting at the clinic for the first time in 2021 (+4% compared to 2019). For all other age groups, the frequency of care seeking was still lower in 2021 than 2019, especially among the oldest patients (> 65 years old). Our results showed also a strong increase in 2021, compared to 2019, of care seeking related to mood and neurotic disorders among 15-24 years old.

Several French studies reported similar findings: diminished healthcare use in 2021 than in the pre-pandemic period, except for the youngest patients, and an increase of depressive and anxiety symptoms in this age group. The French national public health agency (Santé Publique France) reported an increase in 2021 in number of ED visits for suicidal ideation and behaviour and mood disorders among children (0-17 years old) and young adults (18-24 years old) as compared with the previous 3 years[30]. In addition, the emergency general practitioner service (SOS Médecins) reported more medical consultations for anxiety or depressive disorders among young adults in 2021 than in the previous 3 years. Another survey (EpiCov), conducted by the French Institute of Medical Research (INSERM) and the French direction of Research, Studies, Evaluations and Statistics (DREES), reported an improvement in mental health among the general population from March 2020 to November 2020, except for young people (< 25 years old)[31]. Among them, the prevalence of depressive symptoms was still higher in November 2020 than in 2019 (+3 points for minor depressive symptoms and + 6 points for major depressive disorders) but was lower or stable for all other age groups. The situation seems to be more concerning for young women (15-24 years old), with a 23.7% prevalence of depressive symptoms and a 13.4% prevalence of major depressive disorders in November 2020, but respectively 10.7% and 3.7% in 2019. This survey also reported that 5.0% of participants aged 15-24 years old declared having suicidal thoughts over the past 12 months, more frequently reported by young women (6.4%)

than young men (3,6%).. Several studies from other countries also reported a higher prevalence of depressive symptoms and anxiety disorders among young adults in the aftermath of the pandemic, especially young women, confirming the adverse impact of the pandemic on their mental health [32–34].

The reduction in mental healthcare use after the Covid-19–related restrictive measures was also observed in other countries. In the United Kingdom, despite a progression in number of new referrals and patients hospitalised after the lifting of lockdown (May 2020), the numbers were still substantially lower than before the pandemic[16,35]. In contrast, the number of non-face-to-face contacts showed a sizeable increase, which highlights the need to assess the role of telemedicine to manage mental health disorders and monitor patients during and outside of pandemics[16,36].

In our study, there was a strong reduction of mental healthcare seeking among the eldest (over 65 years old), which was also described in other studies[25,37]. Older people may have avoided health services during the Covid-19 pandemic, because of quarantining requirements and fear of infection, and that it may have discouraged them to seek care for their mental health, even after the lifting of restrictive measures. Moreover, some older people who lived alone may encounter difficulties to access health services as usual. Eventually, the fact that the pandemic had a less adverse impact on older people cannot be excluded, as several studies reported lower levels of anxiety and depression among seniors[10,33,34,38].

Regarding the persistency of psychiatric disorders among young adults, months after the easing of Covid-19 restrictions, it seems crucial to ensure access to appropriate care and continuity of care for youth. The pandemic deeply affected the well-being of an age group already known to be vulnerable to mental health problems, as several studies reported before the Covid-19 crisis[39–42]. Adolescents and young adults have undergone many pandemic-related difficulties, with prolonged home-schooling and the need to study remotely

for an entire academic year and with the closure of usual recreation areas (bars, cinemas, nightclubs etc.), not being able to have their normal social routine with friends[13]. Moreover, restrictions led to officious festive gatherings, during which there was a higher risk of excess (substance use, risky behaviours) and potential abuse[43]. Some studies found home lockdown associated with an increase in domestic violence and ill treatment, with children more at risk in the absence of protective factors, such as access to trusted adults outside the household, school professionals, and friends[44,45].

Furthermore, disruption of care or difficulty in accessing medical care could lead to more severe presentations of psychiatric disorders or worsen pre-existing conditions. Previous work showed a resurgence of serious clinical conditions post-lockdown, including increased suicidal ideation and behaviour, and involuntary hospital admissions[20,26]. In addition, the number of suicide attempts among the youngest, including children ≤ 15 years old, has increased substantially since the end of the first Covid-19 wave as compared with previous years[46,47].

Our study was based on systematically collected medical care data provided by the GHU Psychiatry and Neurosciences facilities, over a 3-year period, covering a time before, during and after the Covid-19 pandemic. This large dataset allowed us to describe robust tendencies regarding the use of mental healthcare. Moreover, the GHU Psychiatry and Neurosciences facilities covers a large area (13 of the 20 Parisian arrondissements are linked to the GHU), so our study represents the use of care by a large sample of the population. The main limitation is the absence of information on care outside the hospital, such as private practitioners, including psychiatrists, psychologists, and general practitioners. Individuals with minor mental health problems could also have been referred to other support services, such as helplines. Furthermore, we were not able to distinguish remote medical consultations (telemedicine) from face-to-face outpatient appointments and so could not analyse the proportion of remote consultations in the activity. We need to understand these changes in providing mental health care and evaluate the therapeutic value and patient

satisfaction regarding remote medical appointments. Eventually, low frequencies of admissions for suicidal attempts or ideation prevented us to perform a weekly evolution analysis.

To conclude, the Covid-19 pandemic and the associated restrictive measures used to control the spread of the virus have had severe consequences on populations' mental health, especially among young women. More worrying is the persistence of psychiatric disorders among the youngest, months after the end of restrictions. Further studies are needed to assess the psychological complications associated with the Covid-19 pandemic among young people and to capture the use of mental health care to ensure that this age group benefits from appropriate care.

**Acknowledgments**: This study used the GHU activity data, systematically recorded for any contact with a GHU medical facility. All data were completely anonymised and did not mention patients' information, expect for their age.

**Funding**: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: None declared.

Ethics approval: French national regulation authorities allow hospitals to use medical and administrative information collected through the Programme de médicalisation des systèmes d'information (PMSI), for the purposes of research, studies, or evaluation in the health field, as long as the reference methodologies for health research are respected (MR005). The PMSI database gather retrospective data from administrative and medical files. All data extracted from the PMSI database were completely anonymous. According the French and European laws, there is no requirement for informed consent for this category of study, informing the patient of their right to oppose to the use of their data is sufficient.

Patient consent for publication: Not required

**Provenance and peer review**: Not commissioned; externally peer reviewed.

**Contributors:** The study was planned by AP and VLM. Data extraction was performed by VLM and DS, data analyses by AP. BA, AP and VLM All authors participated to results interpretation and approved the final manuscript.

Data sharing: The data that support the findings are available from the corresponding author, upon reasonable request.





#### References

- Santomauro DF, Mantilla Herrera AM, Shadid J, *et al.* Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *The Lancet* 2021;**398**:1700–12. doi:10.1016/S0140-6736(21)02143-7
- 342 2 Gloster AT, Lamnisos D, Lubenko J, *et al.* Impact of COVID-19 pandemic on mental health: An international study. *PloS One* 2020;**15**:e0244809. doi:10.1371/journal.pone.0244809
- 344 3 Bäuerle A, Teufel M, Musche V, *et al.* Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany. *J Public Health Oxf Engl* 2020;**42**:672–8. doi:10.1093/pubmed/fdaa106
- Wathelet M, Duhem S, Vaiva G, et al. Factors Associated With Mental Health Disorders Among
   University Students in France Confined During the COVID-19 Pandemic. JAMA Netw Open
   2020;3:e2025591. doi:10.1001/jamanetworkopen.2020.25591
- Glowacz F, Schmits E. Psychological distress during the COVID-19 lockdown: The young adults most at risk. *Psychiatry Res* 2020;**293**:113486. doi:10.1016/j.psychres.2020.113486
- Nearchou F, Flinn C, Niland R, *et al.* Exploring the Impact of COVID-19 on Mental Health
  Outcomes in Children and Adolescents: A Systematic Review. *Int J Environ Res Public Health*2020;**17**:E8479. doi:10.3390/ijerph17228479
- Pierce M, Hope H, Ford T, *et al.* Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. *Lancet Psychiatry* 2020;**7**:883–92. doi:10.1016/S2215-0366(20)30308-4
- 358 8 Meherali S, Punjani N, Louie-Poon S, *et al.* Mental Health of Children and Adolescents Amidst 359 COVID-19 and Past Pandemics: A Rapid Systematic Review. *Int J Environ Res Public Health* 360 2021;**18**:3432. doi:10.3390/ijerph18073432
- Tackling the mental health impact of the COVID-19 crisis: An integrated, whole-of-society response. OECD. https://www.oecd.org/coronavirus/policy-responses/tackling-the-mental-health-impact-of-the-covid-19-crisis-an-integrated-whole-of-society-response-0ccafa0b/ (accessed 20 Oct 2021).
- Fancourt D, Steptoe A, Bu F. Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: a longitudinal observational study. *Lancet Psychiatry* 2021;8:141–9. doi:10.1016/S2215-0366(20)30482-X
- Macalli M, Texier N, Schück S, *et al.* A repeated cross-sectional analysis assessing mental health conditions of adults as per student status during key periods of the COVID-19 epidemic in France. *Sci Rep* 2021;**11**:21455. doi:10.1038/s41598-021-00471-8
- 371 12 Bulloch A, Zulyniak S, Williams J, et al. Poor Mental Health during the COVD-19 Pandemic: Effect
   372 Modification by Age. Can J Psychiatry Rev Can Psychiatr 2021;66:827–9.
   373 doi:10.1177/0706743721994408
- 374 13 Mohler-Kuo M, Dzemaili S, Foster S, *et al.* Stress and Mental Health among
  375 Children/Adolescents, Their Parents, and Young Adults during the First COVID-19 Lockdown in
  376 Switzerland. *Int J Environ Res Public Health* 2021;**18**:4668. doi:10.3390/ijerph18094668
- Mengin A, Allé MC, Rolling J, *et al.* [Psychopathological consequences of confinement].
   *L'Encephale* 2020;**46**:S43–52. doi:10.1016/j.encep.2020.04.007
- 379 15 Gómez-Ramiro M, Fico G, Anmella G, et al. Changing trends in psychiatric emergency service
   380 admissions during the COVID-19 outbreak: Report from a worldwide epicentre. J Affect Disord
   381 2021;282:26–32. doi:10.1016/j.jad.2020.12.057

- sante.gouv.fr/publications/etudes-et-resultats/une-degradation-de-la-sante-mentale-chez-lesjeunes-en-2020 (accessed 18 Mar 2022).
- 429 32 Newlove-Delgado T, McManus S, Sadler K, *et al.* Child mental health in England before and during the COVID-19 lockdown. *Lancet Psychiatry* 2021;**8**:353–4. doi:10.1016/S2215-0366(20)30570-8
- 33 O'Connor RC, Wetherall K, Cleare S, *et al.* Mental health and well-being during the COVID-19 pandemic: longitudinal analyses of adults in the UK COVID-19 Mental Health & Wellbeing study.
   434 *Br J Psychiatry* 2021;**218**:326–33. doi:10.1192/bjp.2020.212
- 435 34 Glowacz F, Schmits E. Psychological distress during the COVID-19 lockdown: The young adults most at risk. *Psychiatry Res* 2020;**293**:113486. doi:10.1016/j.psychres.2020.113486
- Howarth A, Munro M, Theodorou A, *et al.* Trends in healthcare utilisation during COVID-19: a longitudinal study from the UK. *BMJ Open* 2021;**11**:e048151. doi:10.1136/bmjopen-2020-048151
- Chen S, Jones PB, Underwood BR, et al. The early impact of COVID-19 on mental health and community physical health services and their patients' mortality in Cambridgeshire and
   Peterborough, UK. *J Psychiatr Res* 2020;**131**:244–54. doi:10.1016/j.jpsychires.2020.09.020
- 37 Seo JH, Kim SJ, Lee M, *et al.* Impact of the COVID-19 pandemic on mental health service use
   443 among psychiatric outpatients in a tertiary hospital. *J Affect Disord* 2021;**290**:279–83.
   444 doi:10.1016/j.jad.2021.04.070
- 38 Bulloch A, Zulyniak S, Williams J, et al. Poor Mental Health during the COVD-19 Pandemic: Effect
   446 Modification by Age. Can J Psychiatry Rev Can Psychiatr 2021;66:827–9.
   447 doi:10.1177/0706743721994408
- 448 39 Auerbach RP, Mortier P, Bruffaerts R, *et al.* WHO World Mental Health Surveys International 449 College Student Project: Prevalence and distribution of mental disorders. *J Abnorm Psychol* 450 2018;**127**:623–38. doi:10.1037/abn0000362
- 40 Mojtabai R, Olfson M, Han B. National Trends in the Prevalence and Treatment of Depression in Adolescents and Young Adults. *Pediatrics* 2016;**138**:e20161878. doi:10.1542/peds.2016-1878
- 41 Ivey-Stephenson AZ, Demissie Z, Crosby AE, *et al.* Suicidal Ideation and Behaviors Among High School Students Youth Risk Behavior Survey, United States, 2019. *MMWR Suppl* 2020;**69**:47–455 55. doi:10.15585/mmwr.su6901a6
- 42 Hertz MF, Barrios LC. Adolescent mental health, COVID-19, and the value of school-community
   457 partnerships. *Inj Prev J Int Soc Child Adolesc Inj Prev* 2021;**27**:85–6. doi:10.1136/injuryprev-2020-044050
- 43 Peraud W, Quintard B, Constant A. Factors associated with violence against women following the COVID-19 lockdown in France: Results from a prospective online survey. *PLOS ONE* 2021;**16**:e0257193. doi:10.1371/journal.pone.0257193
- 44 Augusti E-M, Sætren SS, Hafstad GS. Violence and abuse experiences and associated risk 463 factors during the COVID-19 outbreak in a population-based sample of Norwegian adolescents. *Child Abuse Negl* 2021;**118**:105156. doi:10.1016/j.chiabu.2021.105156
- 465 45 Pannizzotto S, Depuis Z, Frère J, *et al.* [Impact of COVID-19 outbreak on domestic violence and child abuse]. *Rev Med Liege* 2021;**76**:789–93.
- 46 Cousien A, Acquaviva E, Kernéis S, *et al.* Temporal Trends in Suicide Attempts Among Children 468 in the Decade Before and During the COVID-19 Pandemic in Paris, France. *JAMA Netw Open* 469 2021;**4**:e2128611. doi:10.1001/jamanetworkopen.2021.28611

- 47 Yard E, Radhakrishnan L, Ballesteros MF, et al. Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12-25 Years Before and During the COVID-19 Pandemic United States, January 2019-May 2021. MMWR Morb Mortal Wkly Rep 2021;70:888–94. doi:10.15585/mmwr.mm7024e1
- Figure legend:
- Figure 1: Number of healthcare contacts per week, between 2019 and 2021, for all patients.
- Figure 2: Number of healthcare contacts per week, between 2019 and 2021, for patients aged 15-24 years old.
- Figure 3: Number of healthcare contacts per week, between 2019 and 2021, for mood disorders among patients aged 15-24 years old.










Figure 1: Number of healthcare contacts per week, between 2019 and 2021, for all patients. A. Number of new patients per week attending the GHU outpatient clinics; B. Number of emergency department visits per week; C. Number of hospital admissions per week. The weeks of the first (March 17 to May 11, 2020) and second (Oct. 30 to Dec. 15, 2020) lockdowns are presented on the graph in orange and yellow, respectively.









Figure 2: Number of healthcare contacts per week, between 2019 and 2021, for patients aged 15-24 years old. A. Number of new patients per week attending the GHU outpatient clinics; B. Number of emergency department visits per week; C. Number of hospital admissions per week. The weeks of the first (March 17 to May 11, 2020) and second (Oct. 30 to Dec. 15, 2020) lockdowns are presented on the graph in orange and yellow, respectively.






Figure 3: Number of healthcare contacts per week, between 2019 and 2021, for mood disorders among patients aged 15-24 years old. A. Number of hospital admissions per week; B. Number of emergency department visits per week. The weeks of the first (March 17 to May 11, 2020) and second (Oct. 30 to Dec. 15, 2020) lockdowns are presented on the graph in orange and yellow, respectively.

# Supplementary material 1: Frequencies and proportions of emergency visits according to diagnosis by age groups and year, between 2019 and 2021

Table S1.1: Frequencies and proportions of emergency visits of 15-24 years old according to diagnosis, between 2019 and 2021

	2019		202	20	<b>Evolution 2019-2020</b>	202	21	<b>Evolution 2019-2021</b>
	Freq.	%	Freq.	%		Freq.	%	
Mental and behavioural disorders due to psychoactive substance use	83	3%	88	4%	6%	91	3%	10%
Schizophrenia, schizotypal and delusional disorders	456	17%	363	17%	-20%	395	13%	-13%
Mood [affective] disorders	839	31%	687	31%	-18%	1209	39%	44%
Neurotic, stress-related and somatoform disorders	528	20%	502	23%	-5%	752	24%	42%
Behavioural syndromes associated with physiological disturbances and physical factors	68	3%	51	2%	-25%	85	3%	25%
Disorders of adult personality and behaviour	286	11%	196	9%	-31%	252	8%	-12%
Behavioural and emotional disorders (childhood and adolescence onset)	126	5%	132	6%	5%	103	3%	-18%
Non-psychiatric disorders	295	11%	165	8%	-44%	250	8%	-15%
Total patients	2681		2184			3137		

Table S1.2: Frequencies and proportions of emergency visits of 25-44 years old according to diagnosis, between 2019 and 2021

	201	9	202	20	<b>Evolution 2019-2020</b>	202	21	<b>Evolution 2019-2021</b>
	Freq.	%	Freq.	%		Freq.	%	
Mental and behavioural disorders due to psychoactive substance use	267	6%	231	7%	-13%	277	7%	4%
Schizophrenia, schizotypal and delusional disorders	1118	27%	868	27%	-22%	959	24%	-14%
Mood [affective] disorders	1304	31%	1037	32%	-20%	1335	34%	2%
Neurotic, stress-related and somatoform disorders	804	19%	686	21%	-15%	883	22%	10%
Behavioural syndromes associated with physiological disturbances and physical factors	53	1%	30	1%	-43%	37	1%	-30%
Disorders of adult personality and behaviour	242	6%	144	4%	-40%	131	3%	-46%
Behavioural and emotional disorders (childhood and adolescence onset)	27	1%	28	1%	4%	38	1%	41%
Non-psychiatric disorders	365	9%	244	7%	-33%	286	7%	-22%
Total patients	4180		3268			3946		

Table S1.3: Frequencies and proportions of emergency visits of 45-64 years old according to diagnosis, between 2019 and 2021

	2019		202	20	Evolution 2019-	202	D21 Evolution 2019-	
	Freq.	%	Freq.	%	2020	Freq.	%	2021
Mental and behavioural disorders due to psychoactive substance use	154	8%	127	8%	-18%	98	5%	-36%
Schizophrenia, schizotypal and delusional disorders	613	31%	447	27%	-27%	474	26%	-23%
Mood [affective] disorders	738	37%	611	37%	-17%	684	38%	-7%
Neurotic, stress-related and somatoform disorders	238	12%	223	14%	-6%	294	16%	24%
Behavioural syndromes associated with physiological disturbances and physical factors	10	0%	7	0%	-30%	13	1%	30%
Disorders of adult personality and behaviour	65	3%	50	3%	-23%	35	2%	-46%
Behavioural and emotional disorders (childhood and adolescence onset)	11	1%	12	1%	9%	9	0%	-18%
Non-psychiatric disorders	178	9%	167	10%	-6%	204	11%	15%
Total patients	2007		1644			1811		

Table S1.4: Frequencies and proportions of emergency visits of 65 years old and over according to diagnosis, between 2019 and 2021

	2019		202	20	Evolution 2019-	202	21	Evolution 2019-
	Freq.	%	Freq.	%	2020	Freq.	%	2021
Mental and behavioural disorders due to psychoactive substance use	12	3%	12	3%	0%	11	3%	-8%
Schizophrenia, schizotypal and delusional disorders	85	18%	75	20%	-12%	77	19%	-9%
Mood [affective] disorders	249	54%	198	53%	-20%	217	54%	-13%
Neurotic, stress-related and somatoform disorders	66	14%	54	14%	-18%	76	19%	15%
Behavioural syndromes associated with physiological disturbances and physical factors	7	2%	4	1%	-43%	2	0%	-71%
Disorders of adult personality and behaviour	3	1%	7	2%	133%	1	0%	-67%
Non-psychiatric disorders	38	8%	27	7%	-29%	19	5%	-50%
Total patients	460		377			403		

# Supplementary material 2: Frequencies and proportions of hospital admissions according to diagnosis by age groups and year, between 2019 and 2021

Table S2.1: Frequencies and proportions of hospital admissions of 15-24 years old according to diagnosis, between 2019 and 2021

	2019		202	20	Evolution	202	21	Evolution
	Freq.	%	Freq.	%	2019- 2020	Freq.	%	2019- 2021
Mental and behavioural disorders due to psychoactive substance use	71	3%	70	4%	-1%	85	4%	20%
Schizophrenia, schizotypal and delusional disorders	624	26%	546	27%	-13%	490	20%	-21%
Mood [affective] disorders	490	21%	399	20%	-19%	679	28%	39%
Neurotic, stress-related and somatoform disorders	170	7%	147	7%	-14%	161	7%	-5%
Behavioural syndromes associated with physiological disturbances and physical factors	69	3%	48	2%	-30%	42	2%	-39%
Disorders of adult personality and behaviour	178	8%	169	9%	-5%	194	8%	9%
Behavioural and emotional disorders (childhood and adolescence onset)	145	6%	115	6%	-21%	133	6%	-8%
Non-psychiatric disorders	608	26%	493	25%	-19%	625	26%	3%
Total patients	2355		1987			2409		

Table S2.2: Frequencies and proportions of hospital admissions of 25-44 years old according to diagnosis, between 2019 and 2021

	2019		202	20	Evolution 2019- 2020	202	2021	
	Freq.	%	Freq.	%		Freq.	%	
Mental and behavioural disorders due to psychoactive substance use	315	6%	258	6%	-18%	319	7%	1%
Schizophrenia, schizotypal and delusional disorders	1903	35%	1534	35%	-19%	1562	35%	-18%
Mood [affective] disorders	958	18%	809	19%	-16%	1005	22%	5%
Neurotic, stress-related and somatoform disorders	210	4%	150	3%	-29%	163	4%	-22%
Behavioural syndromes associated with physiological disturbances and physical factors	78	1%	44	1%	-44%	47	1%	-40%
Disorders of adult personality and behaviour	228	4%	194	4%	-15%	158	4%	-31%
Behavioural and emotional disorders (childhood and adolescence onset)	52	1%	78	2%	50%	55	1%	6%
Non-psychiatric disorders	1660	31%	1278	29%	-23%	1171	26%	-29%
Total patients	5404		4345			4480		

Table S2.3: Frequencies and proportions of hospital admissions of 45-64 years old according to diagnosis, between 2019 and 2021

	2019		2020		Evolution	2021		Evolution
	Freq.	%	Freq.	%	2019- 2020	Freq.	%	2019- 2021
Mental and behavioural disorders due to psychoactive substance use	230	6%	210	6%	-9%	185	5%	-20%
Schizophrenia, schizotypal and delusional disorders	1408	35%	1124	33%	-20%	1067	30%	-24%
Mood [affective] disorders	898	22%	845	25%	-6%	1145	32%	28%
Neurotic, stress-related and somatoform disorders	105	3%	92	3%	-12%	91	3%	-13%
Behavioural syndromes associated with physiological disturbances and physical factors	13	0%	14	0%	8%	7	0%	-46%
Disorders of adult personality and behaviour	73	2%	83	2%	14%	65	2%	-11%
Behavioural and emotional disorders (childhood and adolescence onset)	19	0%	12	0%	-37%	11	0%	-42%
Non-psychiatric disorders	1322	32%	993	29%	-25%	982	28%	-26%
Total patients	4068		3373			3553		

Table S2.4: Frequencies and proportions of hospital admissions of 65 years old and over according to diagnosis, between 2019 and 2021

	2019		2020		Evolution	2021		Evolution
	Fred. 1% Fred. 1% 1		2019- 2020	Freq.	%	2019- 2020		
Mental and behavioural disorders due to psychoactive substance use	38	2%	24	2%	-37%	22	2%	-42%
Schizophrenia, schizotypal and delusional disorders	344	22%	287	22%	-17%	299	23%	-13%
Mood [affective] disorders	703	44%	664	50%	-6%	553	43%	-21%
Neurotic, stress-related and somatoform disorders	36	2%	31	2%	-14%	45	3%	25%
Behavioural syndromes associated with physiological disturbances and physical factors	3	0%	3	0%	0%	1	0%	-67%
Disorders of adult personality and behaviour	15	1%	12	1%	-20%	15	1%	0%
Behavioural and emotional disorders (childhood and adolescence onset)	6	0%	4	0%	-33%	2	0%	-67%
Non-psychiatric disorders	447	28%	296	22%	-34%	359	28%	-20%
Total patients	1592		1321			1296		

 29 of 33

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items  RECORD items  964 975 975 975 975 975	Location in manuscript where items are reported
Title and abstra	ct			Те ер	
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 1	RECORD 1.1: The type of that used should be specified in the title or abstract. When possible, the mame of the databases used should be included.  RECORD 1.2: If applicable the geographic region and time that within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Page 1-2
Introduction				n/ o	
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4	n April 10	
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5	, 2024 by (	
Methods				guest.	
Study Design	4	Present key elements of study design early in the paper	Page 5	st. Prot	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 5-6	Protected by copyright	

eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants.  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  Page 7  Page 8  Page 8  Page 9	Participants	6	(a) Cohort study - Give the	Page 5	RECORD 6.1: The methods of study	NA
sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  Begorithms used to identify \$\frac{8}{2}\times is not possible, an explanation should be provided.  \$\frac{8}{2}\times 12 \times 12 \tim	-		eligibility criteria, and the			
of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers, Give diagnostic criteria, if applicable.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers, should be provided.  Babould be listed in detail. If this is not possible, an explanation should be provided.  RECORD 6.2: Any validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers should be provided. If these cannot be reported, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.						
methods of follow-up  Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed  Uvariables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was bonducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and effect modifiers should be provided.			of participants. Describe			
Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls   Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants					possible, an explanation should be	
eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 6.2: Any validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confognders, and effect modifiers should be provided. If these cannot be reported, and effect modifiers should be provided.  Page 6						
sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 6.2: Any validation studies of the codes or algorithms used to classify exposures, ontologist to select the population should be referenced. If validation vasconducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other grapheral display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confognders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confognders, and effect modifiers should be provided. If these cannot be reported, and effect modifiers should be provided.			1		23	
ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed  Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  Page 6  Page 6  Page 6  Select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphe all display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  September 1 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6			sources and methods of case		RECORD 6.2: Any validation studies	
selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed  Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  Page 6  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  Page 6  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and exposures are considered and effect modifiers should be provided.  Page 6			ascertainment and control			
the choice of cases and controls  Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed  Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 6.3: If the study igvolved linkage of databases, consider use of a flow diagram or other grapheral display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  Second 7  Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers should be provided. If these cannot be reported, and effect modifiers should be provided.  Data sources/ measurement  RECORD 7.1: A complete last of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete last of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete last of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete last of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.			selection. Give the rationale for			
eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed  Case-control study - For matched studies give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 6.3: If the study igvolved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Data sources/ measurement  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.			the choice of cases and controls			
eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed  Case-control study - For matched studies give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Page 6  RECORD 6.3: If the study igvolved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Data sources/ measurement  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.			Cross-sectional study - Give the		for this study and not published	
sources and methods of selection of participants    Sources and methods of selection of participants   Should be provided.   Section of participants   Should be provided.   Section of participants   Section of adatabases, consider use of a flow diagram or other graphs all display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.   Section of process, including the number of individuals with linked data at each stage.   Section of participants   Sect			eligibility criteria, and the			
RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.    Variables   7   Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.   Page 6						
Content study - For matched studies, give matching criteria and number of exposed and unexposed   Case-control study - For matched studies, give matching criteria and the number of controls per case      Variables   7   Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.   Page 6			of participants			
studies, give matching criteria and number of exposed and unexposed  Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  Studies, give matching criteria and unexposed process, including the number of individuals with linked data at each stage.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6  Page 6					RECORD 6.3: If the study involved	
and number of exposed and unexposed  Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  8 For each variable of interest, give sources of data and details  and number of exposed and to demonstrate the data linkage process, including the number of individuals with linked data at each stage.  NA  RECORD 7.1: A complete lest of codes and algorithms used to classeffy exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.			(b) Cohort study - For matched	76	linkage of databases, consider use of a	
unexposed  Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  Page 6  RECORD 7.1: A complete let of codes and algorithms used to classery exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6  Page 6  RECORD 7.1: A complete let of codes and algorithms used to classery exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.			studies, give matching criteria	1 L	flow diagram or other graphical display	
Case-control study - For matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided.  Page 6			and number of exposed and		to demonstrate the data linkage	
matched studies, give matching criteria and the number of controls per case  Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  matched studies, give matching criteria and the number of controls per case  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.			unexposed	(1).	process, including the number of	
Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  Clearly define all outcomes, Page 6  RECORD 7.1: A complete lest of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6  RECORD 7.1: A complete lest of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.			Case-control study - For		individuals with linked data at each	
Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6  RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6			matched studies, give matching		stage.	
Variables  7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  Page 6  RECORD 7.1: A complete lest of codes and algorithms used to classery exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6  RECORD 7.1: A complete lest of codes and algorithms used to classery exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6			criteria and the number of		ıj. cc	
exposures, predictors, potential confounders, and effect exposures, outcomes, confounders, and modifiers. Give diagnostic effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Data sources/ 8 For each variable of interest, give sources of data and details  Page 6  and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.			controls per case		om/	
confounders, and effect modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  confounders, and effect exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6  exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, and explanation should be provided.	Variables	7	Clearly define all outcomes,	Page 6	RECORD 7.1: A complete lest of codes	NA
modifiers. Give diagnostic criteria, if applicable.  Data sources/ measurement  modifiers. Give diagnostic effect modifiers should be provided. If these cannot be reported, and explanation should be provided.  Page 6  give sources of data and details			exposures, predictors, potential		and algorithms used to class fy	
criteria, if applicable.  these cannot be reported, an these cannot be reported, an these cannot be reported, and explanation should be provided.  Data sources/ measurement  By these cannot be reported, and explanation should be provided.  Page 6			confounders, and effect		exposures, outcomes, confounders, and	
Data sources/ 8 For each variable of interest, give sources of data and details explanation should be provided.  Page 6			modifiers. Give diagnostic		effect modifiers should be provided. If	
Data sources/ 8 For each variable of interest, give sources of data and details			criteria, if applicable.		these cannot be reported, an \( \tilde{\ti}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}	
measurement give sources of data and details					explanation should be provided.	
	Data sources/	8	,	Page 6	gue	
of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	measurement		give sources of data and details		St	
(measurement).  Describe comparability of assessment methods if there is more than one group			of methods of assessment		orot -	
Describe comparability of assessment methods if there is more than one group			` '		ect	
assessment methods if there is more than one group					ed t	
more than one group					) у с	
			more than one group		öp)	

1
2
3
3 4 5 6 7 8 9 10 11 12
5
6
7
8
9
10
11
12
13
15
14 15 16 17 18 19 20
17
12
10
20
21
22
22
21 22 23 24 25 26 27 28 29
25
26
27
20
29
29 30
31
32
33
27
25
34 35 36
37
38 39
39 40
40
41 42
42 43
44 45
45

Bias	9	Describe any efforts to address	NA	pper	
210.0		potential sources of bias		1-20:	
Study size	10	Explain how the study size was arrived at	NA	22-064:	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	Page 6	2-064305 on 23 Februa	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data	Page 6-7	ry 2023. Downloaded fi	
Data access and cleaning methods				RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	Page 5

				T = = = = = = = = = = = = = = = = = = =	
				RECORD 12.2: Authors should	
				provide information on the ta	
				cleaning methods used in the study.	
Linkage				RECORD 12.3: State whether the	NA
				study included person-level,	
				institutional-level, or other data linkage	
				across two or more databases. The	
				methods of linkage and methods of	
				linkage quality evaluation slagould be	
				provided.	
Results				202	
Participants	13	(a) Report the numbers of	NA	RECORD 13.1: Describe in detail the	
1		individuals at each stage of the		selection of the persons incladed in the	
		study (e.g., numbers potentially		study ( <i>i.e.</i> , study population $\frac{3}{8}$ election)	
		eligible, examined for eligibility,		including filtering based on data	
		confirmed eligible, included in		quality, data availability and linkage.	
		the study, completing follow-up,	V <sub>L</sub>	The selection of included persons can	
		and analysed)	1	be described in the text and for by	
		(b) Give reasons for non-		means of the study flow diagram.	
		participation at each stage.		jo	
		(c) Consider use of a flow		<del>p</del> er	
		diagram	10	1.bn	
Descriptive data	14	(a) Give characteristics of study	NA	1.00	
		participants (e.g., demographic,		/mc	
		clinical, social) and information		.com/ on April 10, 2024 by guest.	
		on exposures and potential		Apr	
		confounders		1 10	
		(b) Indicate the number of		5, 2	
		participants with missing data		024	
		for each variable of interest		by	
		(c) <i>Cohort study</i> - summarise		gue	
		follow-up time (e.g., average and		est.	
		total amount)		Pro	
Outcome data	15	Cohort study - Report numbers	Page 8-9-10	Protected by copyrigh	
Saconio data		of outcome events or summary	150 0 7 10	ted	
		measures over time		by	
		Case-control study - Report		сор	
		numbers in each exposure		yrig	
	1	numbers in each exposure		<u> </u>	

	1			₩	
		category, or summary measures		open-2022-064305	
		of exposure		202	
		Cross-sectional study - Report		2-0	
		numbers of outcome events or		643	
		summary measures		305	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-	NA	on 23 February 2023. Downloaded from http://bmjopen.bmj.co	
		adjusted estimates and their		Feb	
		precision (e.g., 95% confidence		ruai	
		interval). Make clear which		7 2	
		confounders were adjusted for		023	
		and why they were included		, D	
		(b) Report category boundaries		Ŏ W	
		when continuous variables were		nloa	
		categorized		åd. @	
		(c) If relevant, consider		d fr	
		translating estimates of relative	76	ă ă	
		risk into absolute risk for a	6	http	
		meaningful time period		;//br	
Other analyses	17	Report other analyses done—	Page 8-9-10	njop	
		e.g., analyses of subgroups and		oen.	
		interactions, and sensitivity		bm	
		analyses		j.co	
Discussion				m/	
Key results	18	Summarise key results with	Page 10	on A	
		reference to study objectives		. pri	
Limitations	19	Discuss limitations of the study,		RECORD 19.1: Discuss the	Page 12
		taking into account sources of		implications of using data that were not	
		potential bias or imprecision.		created or collected to answer the	
		Discuss both direction and		specific research question(s) Include	
		magnitude of any potential bias		discussion of misclassification bias,	
				unmeasured confounding, mussing	
				data, and changing eligibilitg over	
				time, as they pertain to the sudy being	
				reported	
Interpretation	20	Give a cautious overall	Page 11	by copyright.	
		interpretation of results		ору	
	- 1	considering objectives,	1	I ∃.	ĺ

				jo	
		limitations, multiplicity of		Den-	
		analyses, results from similar		202	
		studies, and other relevant		22-(	
		evidence		064:	
Generalisability	21	Discuss the generalisability	Page 12	305	
		(external validity) of the study		o <sub>n</sub>	
		results		23	
Other Information	n			Feb	
Funding	22	Give the source of funding and	Page 13	rua	
		the role of the funders for the		у 2	
		present study and, if applicable,		023	
		for the original study on which		3.° D	
		the present article is based		OWr	
Accessibility of				RECORD 22.1: Authors should	Page 13
protocol, raw		100		provide information on how access	
data, and				any supplemental information such as	
programming			<b>1</b>	the study protocol, raw data, or	
code			1 h	programming code.	

\*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Medicine 2015; in press. omj.com/ on April 10, 2024 by guest. Protected by copyright.

\*Checklist is protected under Creative Commons Attribution (<u>CC BY</u>) license.